Enterprise Value

-36.39M

Cash

94.69M

Avg Qtr Burn

-25.94M

Short % of Float

7.14%

Insider Ownership

14.71%

Institutional Own.

64.61%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Korsuva IV (CR845 IV) Details
Pruritus with chronic kidney disease , Kidney disease

Approved

Quarterly sales

Oral Korsuva (difelikefalin) (CR845) Details
Pruritus with chronic kidney disease , Chronic kidney disease

Phase 3

Data readout

Oral Korsuva (difelikefalin)(CR845) Details
Skin disease/disorder, Inflammatory disease, Atopic dermatitis, Atopic pruritus

Big Mover™

Susp. Mover™

Phase 3

Data readout

Oral Korsuva (difelikefalin) (CR845) Details
Chronic pruritus, Pruritus associated with notalgia paresthetica

Phase 2/3

Data readout

Oral Korsuva (difelikefalin) (CR845) Details
Chronic liver disease, Liver disease, Chronic pruritus, Hemophilia, Blood disorder

Failed

Discontinued